WGO Graded Evidence: Strategies for Reducing the Prevalence of Antimicrobial Resistance

Level: Clinical Trials: 6 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. I Rapti, E Dimou, P Mitsoula, SJ Hadziyannis, Hepatology. 2007 Feb:307-13
	Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group, Hepatology. 2008 Jul;48(1):99-108
	Race, insulin resistance and hepatic steatosis in chronic hepatitis C. HS Conjeevaram, DE Kleiner, JE Everhart, JH Hoofnagle, S Zacks, NH Afdhal, AS Wahed, Virahep-C Study Group, Hepatology. 2007 Jan:80-7
	Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S, Helicobacter. 2009 Feb;14(1):29-35
	Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. S Miehlke, K Hansky, W Schneider-Brachert, C Kirsch, A Morgner, A Madisch, E Kuhlisch, E Bæstlein, E Jacobs, E Bayerd&oeig;rffer, N Lehn, M Stolte, Aliment Pharmacol Ther. 2006 Jul 15:395-403
Supplementary evidence:
	Antimicrobial resistance associated with the treatment of bacterial vaginosis. RH Beigi, MN Austin, LA Meyn, MA Krohn, SL Hillier, Am J Obstet Gynecol. 2004 Oct:1124-9
	First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. TT Koivisto, HI Rautelin, ME Voutilainen, MT Heikkinen, JP Koskenpato, MA Færkkilæ, Aliment Pharmacol Ther. 2005 Mar 15:773-82